Voyager Therapeutics Q4 2024 net loss $34.5M; tau gene therapy VY1706 IND filing planned for 2026

Voyager Therapeutics, Inc.

Net loss $34.5M in Q4 2024 vs net income $56.4M in Q4 2023; full year net loss $65.0M vs income $132.3M.
Collaboration revenue $6.3M in Q4 2024 vs $90.1M in Q4 2023; $80.0M full year vs $250.0M in 2023.
Cash and marketable securities $332.4M as of Dec 31, 2024; runway extended into mid-2027 excluding milestones.
Tau silencing gene therapy VY1706 reduced tau mRNA 50-73% in NHP study; IND filing anticipated in 2026.
Anti-tau antibody VY7523 MAD study initiated; initial tau PET data in Alzheimer's patients expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.